Patents by Inventor Ravindra Kumar

Ravindra Kumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200199547
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 25, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Publication number: 20200199548
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: March 3, 2020
    Publication date: June 25, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Publication number: 20200199186
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 25, 2020
    Applicant: Acceleron Pharma Inc.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Publication number: 20200199546
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 25, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Patent number: 10689427
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: June 23, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Patent number: 10682392
    Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: June 16, 2020
    Assignees: THE BRINGHAM AND WOMEN'S HOSPITAL, INC., ACCELERON PHARMA, INC.
    Inventors: Paul Yu, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves, Ravindra Kumar
  • Publication number: 20200181217
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 11, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Publication number: 20200181218
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: February 19, 2020
    Publication date: June 11, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Patent number: 10679694
    Abstract: PMOS-based temperature compensated read-assist circuits for low-Vmin 6T SRAM bitcells realized in nanometer scale (e.g., 7 nm) CMOS FinFET technologies generate maximum wordline lowering (lower wordline voltages) at higher temperatures and minimum wordline lowering (higher wordline voltages) at lower operating temperatures in way that is substantially process independent and avoids post-silicon tuning. A read-assist PMOS transistor is connected between an associated wordline and VSS and controlled by a temperature compensation signal produced at an intermediate node between weak pull-up and strong pull-down PMOS transistors that are connected in series between VDD and VSS and respectively controlled by VDD and VSS during read operations. This configuration generates the temperature compensation signal at a level closer to VSS at high temperatures than at low temperatures, whereby write-ability is not impacted by the read-assist circuit at low temperature.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: June 9, 2020
    Assignee: Synopsys, Inc.
    Inventors: Vinay Kumar, Ravindra Kumar Shrivastava
  • Publication number: 20200164029
    Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to treat fibrotic disorders.
    Type: Application
    Filed: September 5, 2019
    Publication date: May 28, 2020
    Applicant: Acceleron Pharma Inc.
    Inventors: Asya Grinberg, Roselyne Castonguay, Eric Werner, Ravindra Kumar
  • Publication number: 20200165583
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: June 27, 2019
    Publication date: May 28, 2020
    Inventors: Jasbir Seehra, Robert Scott Pearsall, Ravindra Kumar
  • Publication number: 20200157182
    Abstract: In certain aspects, the present disclosure relates to polypeptides comprising a truncated, ligand-binding portion of the extracellular domain of T?RII polypeptide useful to selectively antagonize a T?RII ligand. The disclosure further provides compositions and methods for use in treating or preventing TGF? associated disorders.
    Type: Application
    Filed: January 30, 2020
    Publication date: May 21, 2020
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne S. Sako, Roselyne Castonguay, Rita Steeves
  • Publication number: 20200157512
    Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.
    Type: Application
    Filed: June 7, 2019
    Publication date: May 21, 2020
    Inventors: Jasbir Seehra, Ravindra Kumar
  • Publication number: 20200148788
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
    Type: Application
    Filed: June 12, 2019
    Publication date: May 14, 2020
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Publication number: 20200115428
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Application
    Filed: May 24, 2019
    Publication date: April 16, 2020
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani, John Knopf
  • Patent number: 10616044
    Abstract: A system uses event correlation to identify components belonging to a same service or service domain. The system correlates events by generating covariance matrices or by performing sequence mining with temporal databases in order to discover event patterns that occur sequentially in a fixed time window. Components corresponding to the correlated events are identified as being part of a same service domain and can be indicated in a service domain data structure, such as a topology. The system utilizes the identified service domains during root cause analysis. The system can determine an anomalous event occurring a lowest layer component in a service domain as a root cause or can determine an anomalous event which occurs first in an identified event sequence of a service domain as a root cause. After identifying the root cause event, the system suppresses notifications of events occurring at other components in the service domain.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: April 7, 2020
    Assignee: CA, Inc.
    Inventors: Balram Reddy Kakani, Ravindra Kumar Puli, Smrati Gupta
  • Publication number: 20200106660
    Abstract: A system uses event correlation to identify components belonging to a same service or service domain. The system correlates events by generating covariance matrices or by performing sequence mining with temporal databases in order to discover event patterns that occur sequentially in a fixed time window. Components corresponding to the correlated events are identified as being part of a same service domain and can be indicated in a service domain data structure, such as a topology. The system utilizes the identified service domains during root cause analysis. The system can determine an anomalous event occurring a lowest layer component in a service domain as a root cause or can determine an anomalous event which occurs first in an identified event sequence of a service domain as a root cause. After identifying the root cause event, the system suppresses notifications of events occurring at other components in the service domain.
    Type: Application
    Filed: September 28, 2018
    Publication date: April 2, 2020
    Inventors: Balram Reddy Kakani, Ravindra Kumar Puli, Smrati Gupta
  • Patent number: 10603359
    Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: March 31, 2020
    Assignee: ACCELERON PHARMA INC.
    Inventors: Ravindra Kumar, Naga Venkata Sai Rajasekhar Suragani
  • Publication number: 20200087406
    Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
    Type: Application
    Filed: November 26, 2019
    Publication date: March 19, 2020
    Inventors: John Knopf, Jonathan Belk, Nathan J. Sharkey, Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay, Yossi Dagon
  • Publication number: 20200071382
    Abstract: The present invention discloses heterodimers comprising endoglin-Fc and ALKI-Fc, or hetero dimers comprising endoglin-Fc and ALK2-Fc. The Fe domains can include amino acid mutations that promote heterodimer formation. In certain aspects, the disclosure provides heteromeric polypeptide complexes comprising a co-receptor of the TGF-beta superfamily and an extracellular domain of a type I serine/threonine kinase receptor of the TGF beta superfamily, an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta superfamily, or an additional co-receptor of the TGF-beta superfamily. In some embodiments, the disclosure provides heteromultimers comprising a ligand-domain of one or more co-receptor selected from: endoglin, Cripto-1, Cryptic, Cryptic family protein IB, CRIMI, CRIM2, BAMBI, BMPER, RGM-A, RGMB, hemojuvelin, betaglycan, and MuSK.
    Type: Application
    Filed: July 6, 2017
    Publication date: March 5, 2020
    Applicant: Acceleron Pharma Inc.
    Inventors: Ravindra Kumar, Asya Grinberg, Dianne Sako, Roselyne Castonguay